INKON Life Technology Co., Ltd. is a China-based healthcare technology and medical services enterprise that operates an integrated oncology and clinical care ecosystem encompassing medical device manufacturing and healthcare facility operations. Founded in 1998 and headquartered in Dongguan, China, and operating as a core clinical healthcare platform under the Haier Group ecosystem, the company serves healthcare institutions and patients domestically and internationally across the continuum of cancer prevention, screening, diagnosis, treatment, and rehabilitation. INKON Life Technology operates primarily through two business segments: Medical Equipment and Medical Services. The Medical Equipment segment researches, manufactures, and distributes advanced radiotherapy, imaging, and life support systems, including stereotactic gamma-ray radiosurgery systems such as head and body Gamma Knife devices developed through its subsidiary Masep Medical Science and Technology; high-pressure contrast media delivery injectors, including the Discovery D series for computed tomography, magnetic resonance imaging, and digital subtraction angiography, along with matching syringe and tubing consumables produced via its Shenzhen Saintnode Medical subsidiary; AI-assisted digital mammography systems for early tumor screening; and smart infusion pumps, target-controlled infusion devices, and chronic disease management equipment. The Medical Services segment owns, operates, and manages oncology-specialized and general hospitals, offering inpatient and outpatient medical services; surgical oncology; precision stereotactic radiotherapy; medical oncology and chemotherapy; diagnostic laboratory and imaging services; critical care management; and comprehensive post-acute rehabilitation and elderly nursing care across a tiered network of medical centers. In recent developments, INKON Life Technology has accelerated the integration of artificial intelligence and Internet of Things technologies across its clinical solutions, launching AI-enhanced diagnostic mammography platforms and intelligent pressure-monitoring contrast injector systems. The company has also deepened operational synergies and expanded production capabilities following the integration of Shenzhen Saintnode Medical, advanced its proprietary high-end radiotherapy platforms, expanded clinical treatment capacities for complex oncology surgeries across its hospital network, and strategically broadened its institutional service footprint across serious illness treatment, intensive rehabilitation, and eldercare nursing.